Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Interactome of human and SARS-CoV-2 proteins to identify human hub proteins associated with comorbidities

Nimisha Ghosh a,b,1, Indrajit Saha c,*1, Nikhil Sharma d

a Department of Computer Science and Information Technology, Institute of Technical Education and Research, Siksha ‘O’ Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, India
b Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw, Poland
c Department of Computer Science and Engineering, National Institute of Technical Teachers’ Training and Research, Kolkata, West Bengal, India
d Department of Electronics and Communication Engineering, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India

ARTICLE INFO

Keywords:
COVID-19
Comorbidities
Hub proteins
Protein-protein interaction
Repurposable drugs
SARS-CoV-2

ABSTRACT

SARS-CoV-2 has a higher chance of progression in adults of any age with certain underlying health conditions or comorbidities like cancer, neurological diseases and in certain cases may even lead to death. Like other viruses, SARS-CoV-2 also interacts with host proteins to pave its entry into host cells. Therefore, to understand the behaviour of SARS-CoV-2 and design of effective antiviral drugs, host-virus protein-protein interactions (PPIs) can be very useful. In this regard, we have initially created a human-SARS-CoV-2 PPI database from existing works in the literature which has resulted in 7085 unique PPIs. Subsequently, we have identified at most 10 proteins with highest degrees viz. hub proteins from interacting human proteins for individual virus protein. The identification of these hub proteins is important as they are connected to most of the other human proteins. Consequently, when they get affected, the potential diseases are triggered in the corresponding pathways, thereby leading to comorbidities. Furthermore, the biological significance of the identified hub proteins is shown using KEGG pathway and GO enrichment analysis. KEGG pathway analysis is also essential for identifying the pathways leading to comorbidities. Among others, SARS-CoV-2 proteins viz. NSP2, NSP5, Envelope and ORF10 interacting with human hub proteins like COX4I1, COX5A, COX5B, NDUFS1, CANX, HSP90AA1 and TP53 lead to comorbidities. Such comorbidities are Alzheimer, Parkinson, Huntington, HTLV-1 infection, prostate cancer and viral carcinogenesis. Subsequently, using Enrichr tool possible repurposable drugs which target the human hub proteins are reported in this paper as well. Therefore, this work provides a consolidated study for human-SARS-CoV-2 protein interactions to understand the relationship between comorbidity and hub proteins so that it may pave the way for the development of anti-viral drugs.

1. Introduction

SARS-CoV-2, the virus responsible for COVID-19 has disrupted our daily lives and even after almost two years, we are still struggling in our fight against the virus. Though it originated in China, in a short time COVID-19 cases were reported from all around the globe. By September 2021, more than 229 million people have been affected by this virus with more than 4 million deaths. The usual symptoms of COVID-19 range from common cough and cold, shortness of breath, fever to multiple organ failure which may eventually lead to death. Since this is a RNA virus, it shows high mutations and new strains of the virus are also in circulation right now. According to W.H.O, the strains of the virus declared as variants of concern are Alpha or B.1.1.7, Beta or B.1.351, Gamma or P.1 and Delta or B.1.617.2 [1–3].

SARS-CoV-2 encompasses four structural proteins, spike glycoprotein, envelope, membrane glycoprotein and nucleocapsid, apart from non-structural proteins (NSP1-NSP16) and accessory proteins like ORF3a, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10 [4]. Viruses are incapable of living and reproducing outside a host body. Thus, they need to infiltrate a host for their survival. Protein-protein
interaction (PPI) is one such way by which a virus invades a host cell [5]; SARS-CoV-2 being no exception. For SARS-CoV-2, bats are supposed to be the primary hosts and pangolins are identified to be the possible intermediate hosts from which the virus got transmitted to humans resulting in COVID-19 disease [6–8]. Furthermore, knowledge of virus invasion and pathogenesis of SARS-CoV-2 is very important to understand the comorbidities in human host. In this regard, study of PPI is crucial and helpful in drug repurposing and discovery as well. These facts have motivated us to conduct this research.

Traditionally, the collection of PPI data is mainly done through laboratory-based methods such as protein-chips [9,10], correlated mRNA expression profile [11], TAP-tagging [12,13], yeast-two hybrid [14,15] and synthetic lethal analysis [16]. However, laboratory based methods are mostly time consuming and labour-intensive. Also, due to the voluminous nature of PPI data there is a chance that PPI data generated by laboratory-based methods may not be complete [17]. Furthermore, small proteins are difficult to recognise in lab set up although they have important functional roles in many biological processes [18]. Moreover, it has been frequently observed that high false positives and false negatives occur in the prediction results of laboratory-based methods [19–21]. To mitigate these problems, a large number of computational methods have been proposed in the literature to identify protein-protein interactions. In this regard, a very popular method to predict PPI is link prediction model where it is considered that proteins interact if they are similar [22]. However, the accuracy of such models are heavily dependent on the reliability of PPI networks which may be affected due to a huge number of false-negative and false-positive PPIs. Also, in scale-free property of PPI networks [23,24], some PPI are dense while others are mostly sparse (average degree of 7 or less [25]) and link predictive models are not very efficient for sparse networks. Thus, high throughput technologies which consider biological information of proteins can be used to predict PPIs [26]. In Ref. [27], the authors have used bioinformatics and machine learning approaches to identify potential drug targets and pathways in COVID-19. In this regard, they have identified 1520 and 1733 differentially expressed genes (DEGs) from GSE152418 and CRA002390 PBMC datasets and have considered hub gene signature based on module membership (MMhub) statistics and PPI networks. Furthermore, they have demonstrated the classification performance of hub genes with more than 90% accuracy, thereby suggesting the potential of the hub genes to be biomarkers. Gupta et al. [28] have also used machine learning for prediction of new small molecule modulators of PPI. In their work, they have concluded that Random Forest predicts general PPI Modulators independent of PPI network. For our work, initially we have prepared a consolidated human-SARS-CoV-2 PPI database taking into consideration the PPIs from the existing works in the literature which have thereafter resulted in 7085 unique PPIs, identified human hub proteins using such PPI networks and finally identified the list of repurposable drugs for such human hub proteins as well as comorbidity issues related to such hub proteins. To the best of our knowledge, these consolidated ideas have not been addressed previously in any article. Therefore, this study mitigates the gaps in the literature through the above mentioned contributions. It is to be noted that other works like [41,42] have analysed drug repurposibility and comorbidities by considering expression data as opposed to our work which directly considers PPI data for the above analysis.

2. Materials and methods

In this section, the data preparation is elaborated at first which is then followed by the discussion on the pipeline of the proposed work.

2.1. Data preparation

For our work, initially we have prepared a consolidated human-SARS-CoV-2 PPI database taking into consideration the PPIs from Refs. [4,5,43]. There are 332 PPIs in Ref. [4] whereas [5] has reported 6489 PPIs and Li et al. [43] have reported 295 PPIs. Considering all the PPIs between human and SARS-CoV-2, 7085 unique PPIs are identified among 2204 unique human proteins and 4 structural and 25 non-structural virus proteins which include NSP1-16, Spike glycoprotein, ORF3a, ORF3b, Envelope protein, Membrane glycoprotein, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c, Nucleocapsid and ORF10.

2.2. Pipeline of the work

The pipeline of the work is shown in Fig. 1(a). Initially, to create a consolidated human-virus PPI database, 7166 interactions are collected from the existing works in the literature which have thereafter resulted in 7085 unique PPIs. The distribution of the PPIs in the literature is shown in Fig. 1(b). Thereafter, all the human proteins for a particular virus protein are given as an input to the STRING database. STRING database returns all the human-virus human interaction pairs which are provided as inputs. It may also exclude some human proteins in the process as well. Next, for each SARS-CoV-2 protein, at most 10 human proteins viz. hub proteins are identified which have the highest degrees. It is important to note that based on their association with an individual SARS-CoV-2 protein, there are two levels of human proteins, Level 1 and Level 2 as shown in Fig. 1(c). Level 1 human proteins are those which are in the immediate vicinity or directly connected to the
SARS-CoV-2 protein while Level 2 are such human proteins which are indirectly connected to the virus protein through the Level 1 proteins. Among the 10 proteins as shown in the figure, A, C and G are considered to be the hub proteins as they have the highest degree among all the human proteins. Thus, a hub protein can either be a level 1 or a level 2 human protein. It is worth mentioning over here that a level 2 hub protein can be connected to the virus protein either through a hub protein or any directly connected human protein which may not be a hub protein. In this paper, the direct or level 1 hub proteins are marked in red while the indirect or level 2 hub proteins are marked in green and the rest of the human proteins are marked in yellow. SARS-CoV-2 proteins on the other hand are marked in blue throughout the paper. Once the hub proteins are identified, to understand the effects of these hub proteins on comorbidities, their pathways are explored and the

| Virus Protein | Number of Unique Human Proteins directly interacting with SARS-CoV-2 proteins | Number of Unique Human Proteins present in Human PPI network | Number of Unique Human Hub Proteins (out of top 10) directly interacting with SARS-CoV-2 proteins | Number of Unique Human Hub Proteins (out of top 10) indirectly interacting with SARS-CoV-2 proteins | Number of Unique Human Proteins (other than hub proteins) directly connected to Hub Proteins |
|--------------|---------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| NSP1         | 7                                                                                | 4                                                       | 4                                                                                                | 0                                                                                                | 0                                                                                           |
| NSP2         | 15                                                                               | 9                                                       | 8                                                                                                | 1                                                                                                | 0                                                                                           |
| NSP3         | 85                                                                               | 72                                                      | 10                                                                                                | 0                                                                                                | 32                                                                                          |
| NSP4         | 10                                                                               | 6                                                       | 5                                                                                                | 1                                                                                                | 0                                                                                           |
| NSP5         | 100                                                                              | 87                                                      | 10                                                                                                | 0                                                                                                | 35                                                                                          |
| NSP6         | 4                                                                                | 2                                                       | 1                                                                                                | 1                                                                                                | 0                                                                                           |
| NSP7         | 830                                                                              | 788                                                     | 9                                                                                                | 1                                                                                                | 469                                                                                         |
| NSP8         | 50                                                                               | 39                                                      | 10                                                                                                | 0                                                                                                | 16                                                                                          |
| NSP9         | 19                                                                               | 13                                                      | 9                                                                                                | 1                                                                                                | 1                                                                                           |
| NSP10        | 34                                                                               | 27                                                      | 10                                                                                                | 0                                                                                                | 10                                                                                          |
| NSP11        | 1                                                                                | 11                                                      | 1                                                                                                | 9                                                                                                | 1                                                                                           |
| NSP12        | 54                                                                               | 32                                                      | 9                                                                                                | 1                                                                                                | 15                                                                                          |
| NSP13        | 42                                                                               | 29                                                      | 10                                                                                                | 0                                                                                                | 11                                                                                          |
| NSP14        | 10                                                                               | 2                                                       | 2                                                                                                | 0                                                                                                | 0                                                                                           |
| NSP15        | 29                                                                               | 11                                                      | 8                                                                                                | 2                                                                                                | 1                                                                                           |
| NSP16        | 2                                                                                | NA                                                      | NA                                                                                                | NA                                                                                                | NA                                                                                          |
| Spike        | 317                                                                              | 302                                                     | 10                                                                                                | 0                                                                                                | 158                                                                                         |
| glycoprotein |                                                                   |              |                                                                                                    |                                                                                     |                                                                                            |
| ORF3a        | 59                                                                               | 44                                                      | 9                                                                                                | 1                                                                                                | 16                                                                                          |
| ORF3b        | 1                                                                                | 11                                                      | 1                                                                                                | 9                                                                                                | 1                                                                                           |
| Envelope     | 1141                                                                             | 1086                                                   | 10                                                                                                | 0                                                                                                | 673                                                                                         |
| Membrane     | 107                                                                              | 81                                                      | 9                                                                                                | 1                                                                                                | 36                                                                                          |
| glycoprotein |                                                                   |              |                                                                                                    |                                                                                     |                                                                                            |
| ORF6         | 1236                                                                             | 1194                                                   | 9                                                                                                | 1                                                                                                | 677                                                                                         |
| ORF7a        | 148                                                                               | 133                                                     | 9                                                                                                | 1                                                                                                | 55                                                                                          |
| ORF7b        | 987                                                                               | 951                                                     | 9                                                                                                | 1                                                                                                | 611                                                                                         |
| ORF8         | 106                                                                               | 82                                                      | 10                                                                                                | 0                                                                                                | 42                                                                                          |
| Nucleocapsid | 28                                                                                | 23                                                      | 10                                                                                                | 0                                                                                                | 7                                                                                           |
| ORF9a        | 534                                                                               | 513                                                     | 9                                                                                                | 1                                                                                                | 331                                                                                         |
| ORF9c        | 26                                                                                | 10                                                      | 9                                                                                                | 1                                                                                                | 0                                                                                           |
| ORF10        | 1103                                                                              | 1057                                                    | 9                                                                                                | 1                                                                                                | 635                                                                                         |
biological significance are demonstrated using KEGG pathway and GO enrichment analysis. KEGG pathway analysis is also important for identifying the pathways leading to comorbidities. Finally, identification of potential repurposable drugs targeting the human hub proteins to curb the effects of COVID-19 are carried out using Enrichr\(^5\) tool.

3. Results

This work is executed according to the pipeline as shown in Fig. 1(a). In this work, the primary motivations are to create a human-virus PPI interacting database and identifying the human hub proteins to understand their effects in comorbidities. In this regard, we have collected 7085 unique PPIs from the existing works in the literature, the details of which are provided in the Supplementary. Subsequently, with all the human-human interaction networks collected for each virus protein, the degree of each human protein with respect to a SARS-CoV-2 protein in the PPI network is identified. The degrees of the human proteins are provided in the Supplementary. Once the degree of each human protein for the corresponding SARS-CoV-2 protein is computed, at most top 10 human proteins are selected with the highest degrees which are then considered to be the hub proteins for each virus protein. The details of the top 10 human proteins for each virus protein are reported in Table 1. This table shows the number of unique human proteins directly interacting with SARS-CoV-2 proteins, number of unique human proteins present in human PPI network considering proteins directly interacting with SARS-CoV-2 proteins, number of unique human hub proteins (out of top 10) directly interacting with SARS-CoV-2 proteins, number of unique human hub proteins (out of top 10) indirectly interacting with SARS-CoV-2 proteins and number of unique human proteins apart from the hub proteins directly connected to the hub proteins. As has been mentioned earlier, not all human proteins directly interacting with the SARS-CoV-2 proteins may be a part of the PPI network. This can be inferred from Table 1 as well. For example, for NSP1, 4 human proteins are present in the PPI network while 7 human proteins are directly interacting with SARS-CoV-2 proteins. The corresponding graph for the number of human proteins directly interacting with the SARS-CoV-2 proteins is shown in Fig. 1(d). The sum of interactions or the total degree of the human proteins in human PPI interactome with respect to the virus protein is shown in Fig. 1(e). For example, NSP7 has a total of 53448 human PPI interactions. It can be seen from the figure that out of the 29 virus proteins, 28 has corresponding human-human interaction networks while NSP16 does not have any associated human-human protein interactions.

All the identified human hub proteins may not be directly interacting with the SARS-CoV-2 proteins, rather they may be connected indirectly. For example, for NSP7, out of the 10 hub proteins, 9 such proteins are directly interacting with the SARS-CoV-2 protein while 1 human hub protein is indirectly interacting with the virus protein through some other human proteins. It is to be noted that for SARS-CoV-2 proteins like NSP1, NSP2, NSP4, NSP6 and NSP14 which have corresponding interacting human proteins equal to 7, 15, 10, 4 and 10 respectively have number of hub proteins equal to 4, 9, 6, 2 and 2, less than 10. The details of the human hub proteins for each protein of SARS-CoV-2 are provided in the Supplementary.

Table 1 as well. For example, for NSP1, 4 human proteins are present in the PPI network while 7 human proteins are directly interacting with SARS-CoV-2 proteins. The corresponding graph for the number of human proteins directly interacting with the SARS-CoV-2 proteins is shown in Fig. 1(d). The sum of interactions or the total degree of the human proteins in human PPI interactome with respect to the virus protein is shown in Fig. 1(e). For example, NSP7 has a total of 53448 human PPI interactions. It can be seen from the figure that out of the 29 virus proteins, 28 has corresponding human-human interaction networks while NSP16 does not have any associated human-human protein interactions.

Thus, no more than 30 human proteins (≤10 hub proteins and ≤20 other proteins) are considered for visualization purpose in Fig. 3. The details of all the human-SARS-CoV-2 PPI corresponding to only the hub proteins for each virus protein along with the details of all such interactions for each virus protein irrespective of the hub proteins are provided in the Supplementary.

4. Discussion

4.1. KEGG pathway analysis

KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis reveals the potential diseases that can develop in humans due to SARS-CoV-2. Hub proteins are the ones which are connected to most of the other human proteins in the PPI network. Thus, instead of considering all the human proteins that have been returned by the STRING database, for the KEGG pathway analysis only the hub proteins and those human proteins which are directly connected to the hub proteins are considered. Table 3 reports such maximum 5 significant KEGG pathways (if there are any) with the corresponding hub proteins related to them and their FDR corrected p-values. The detailed pathways are provided in the Supplementary. These results are collected from STRING database. Fig. 4 shows the KEGG pathways for NSP2, NSP5, Envelope protein and ORF10. For better visualization, maximum top 30 pathways are shown in the figures. The size of the bubbles in the figures are based on the corresponding number of human hub proteins associated with each pathway; lesser the number of hub proteins, smaller are the size of the bubbles while their colours are based on the FDR-corrected p-values. It can be seen from Fig. 4 that the most significant pathways corresponding to hub proteins for a SARS-CoV-2 protein are involved in various diseases. For example, for the human hub proteins targeted by NSP2 are enriched in pathways relating to hsa05010: Alzheimer’s disease, hsa05012: Parkinson’s disease and hsa05016: Huntington’s disease with the respective FDR corrected p-value being 4.51E-06 for all the three pathways while the corresponding hub proteins targeted by NSP2 are COX4I1, COXSA, COX5B and NDUF51. SARS-CoV-2 can aggravate cancer pathways as well. For example, human hub protein CANX targeted by NSP5 is enriched in pathway for hsa05166: HTLV-I infection (FDR-corrected p-value 3.20E-03) which is associated with aggressive adult T-cell lymphoma, GAPDH targeted by Envelope protein is enriched in pathway for hsa04662: HIV-1 signaling pathway (FDR-corrected p-value 2.50E-04) while HSP90AA1 is enriched in pathways for hsa04151: PI3K-Akt signaling pathway (FDR-corrected p-value 1.30E-03), hsa05215: Prostate cancer (FDR-corrected p-value 1.24E-02), hsa05200: Pathways in cancer (FDR-corrected p-value 1.26E-02) and EEF2 is responsible for hsa04010: AMPK signaling pathway (FDR-corrected p-value 4.80E-04). Furthermore, RPN1, SEC61A1, CANX and HSP90B1 all targeted by NSP5 are enriched in the pathway for hsa01414: Protein processing in endoplasmic reticulum (FDR-corrected p-value 2.37E-07) and there are studies [47,48] which show that prolonged endoplasmic reticulum stress is responsible for the development and progression of many diseases like atherosclerosis, neurodegeneration, liver disease, type 2 diabetes and cancer. Moreover, TP53 targeted by ORF10 is enriched in the...
A pathway relating to \textit{hsa05203: Viral carcinogenesis} (FDR-corrected p-value 1.70E-04). Other significant pathways found for the human proteins with FDR corrected p-values within 5% statistical significance are \textit{Influenza A}, \textit{Measles, Epstein-Barr Virus infection} and \textit{Vibrio cholerae infection}.

### 4.2. Gene ontology (GO) enrichment analysis

GO enrichment analysis is performed to understand the significance of the roles that the different interacting human proteins play in biological activities. Similar to KEGG pathways, the GO enrichment results are collected from STRING database as well and considered only for the hub proteins and their direct connections. The result of the analysis for Table 2 Details of Human Hub Proteins for each SARS-CoV-2 Protein.

| Virus | Human hub proteins (out of top 10) | Degree of Human hub proteins directly interacting with SARS-CoV-2 proteins | Human hub proteins (out of top 10) indirectly interacting with SARS-CoV-2 proteins | Degree of Human hub proteins indirectly interacting with SARS-CoV-2 proteins |
|-------|-----------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|      |                                   | 3, 3, 3, 3, 1, 1, 1, 1, 1, 1                                              | NA                                                                               | KIAA01033                                        |
|      |                                   | 30, 29, 28, 27, 27, 27, 26, 26, 26                                         | NA                                                                               | NA                                               |
|      |                                   | 3, 3, 3, 1, 1                                                               | NA                                                                               | C19orf52                                         |
|      |                                   | 16, 16, 15, 15, 14, 13, 12, 12, 12                                          | NA                                                                               | NA                                               |
|      |                                   | 1                                                                           | ATP5L                                                                           | 1                                               |
|      |                                   | 259, 251, 243, 236, 232, 231, 222, 221, 219                                  | NHP2L1                                                                          | 238                                             |
|      |                                   | 13, 10, 9, 8, 8, 7, 7, 7, 7                                               | NA                                                                               | NA                                               |
|      |                                   | 6, 6, 6, 5, 4, 2, 1, 1                                                     | NUP1L                                                                          | 4                                               |
|      |                                   | 8, 4, 4, 3, 2, 2, 2, 2, 2                                                 | NA                                                                               | NA                                               |
|      |                                   | 10                                                                          | TBCD, TBCE, TUBA1A, TUBA4A, TUBB1, TUBA26, TUBB28, TUBB4A, TUBB4B KH4orf166 | 10, 10, 10, 10, 10, 10, 10, 10, 10, 10          |
|      |                                   | 11, 10, 10, 8, 7, 7, 7, 5, 5                                              | NA                                                                               | 4                                               |
|      |                                   | 17, 17, 14, 12, 12, 11, 11, 10, 10                                          | NA                                                                               | NA                                               |
|      |                                   | 3, 3, 2, 1, 1, 1, 1, 1                                                    | NA                                                                               | KIAA0020, TCEB3                                  |
|      |                                   | NA                                                                          | NA                                                                               | NA                                               |
|      |                                   | 14, 13, 10, 10, 8, 8, 8, 7, 7                                              | NA                                                                               | 7                                               |
|      |                                   | 10                                                                          | PHB2, YME1L1, PARL, PHB, SMATDL, ATPS1A, MRPL40, HSPA1A, HSPA1L                 | 6, 6, 5, 5, 4, 3, 2                            |
|      |                                   | 301, 286, 279, 268, 260, 256, 254, 253, 251, 248                           | NA                                                                               | NA                                               |
|      |                                   | 12, 12, 10, 10, 10, 9, 8, 8                                               | ATP5O                                                                          | 7                                               |
|      |                                   | 320, 312, 307, 306, 305, 302, 302, 299, 299                                | NHP2L1                                                                          | 7                                               |
|      |                                   | 32, 29, 28, 22, 21, 21, 21, 20                                              | SKIV2L                                                                          | 22                                              |
|      |                                   | 284, 273, 273, 264, 258, 248, 248, 245, 244                                | NHP2L1                                                                          | 262                                             |
|      |                                   | 24, 23, 21, 20, 19, 19, 19, 18, 18                                           | NA                                                                               | NA                                               |
|      |                                   | 10, 9, 8, 8, 5, 5, 5, 5, 4                                                | NA                                                                               | NA                                               |
|      |                                   | 185, 177, 177, 176, 175, 173                                              | GNR2L1                                                                          | 171                                             |
|      |                                   | 4, 3, 3, 2, 2, 2, 2, 2, 2, 1                                               | FAM134C                                                                         | 1                                               |
|      |                                   | 282, 272, 269, 264, 260, 256, 252, 251, 251                                 | NHP2L1                                                                          | 265                                             |
biological processes for NSP2, NSP5, Envelope protein and ORF10 considering at least one hub protein are reported in Fig. 5. For better readability, only the top 30 pathways are shown in the figures. The detailed analysis for all the GO pathways (biological, molecular and cellular) are provided in the Supplementary. Some significant biological pathways for human hub proteins COX5B, COX5A and COX4I1 targeted by NSP2 are: GO:0006123: mitochondrial electron transport, cytochrome c to oxygen (FDR-corrected p-value 1.11E-05), hub proteins HSP90B1, P5MC6 and PSMD14 targeted by NSP5: GO:0030163: protein catabolic process (FDR-corrected p-value 1.34E-06), HSPA8, RPS27A, HNRNPA1, EIF4A3, RPL4 and RPS3 targeted by Envelope protein: GO:0016071: mRNA metabolic process (FDR-corrected p-value 4.13E-123) and HSPA8, RPS27A, NHP2L1, EIF4A3, HNRNPA1, RPL4, RPS20, RPS3 and TP53 targeted by ORF10: GO:0016071: mRNA metabolic process (FDR-corrected p-value 6.46E-132).

4.3. Repurposable drugs

Till now, no efficacious drug has been discovered to combat SARS-CoV-2. The traditional mechanism of drug development is expensive and time-consuming, thereby making drug repurposing a viable option for effective drug identification for COVID-19. In this regard, human hub proteins corresponding to each SARS-CoV-2 protein can be considered to be good candidates as targets for drug repurposing. Such drugs that interact with the hub proteins are identified using DSigDB in Enrichr tool. For each virus protein, the results for at most top 5 drugs (if any) along with their Drug Bank ID as collected from Drug Bank, their FDR corrected p-values and the possible treatments are reported in Table 4.

As can be seen from Table 4, several drugs are identified which can be used for treating cancer. For example, Tanespimycin (FDR corrected p-value 4.44E-03 and Drug Bank ID DB05134) which targets human hub protein like HSP90AA1 corresponding to Envelope protein is used for treating several types of cancer, solid tumors or chronic myelogenous leukemia. As previously discussed, HSP90AA1 which is targeted by SARS-CoV-2 Envelope protein triggers PI3K-Akt signaling pathway whose aberrant activation promotes the survival and growth of tumor cells in many human cancers. Other drugs like Phenethyl isothiocyanate, 4-Hydroxytamoxifen, Daunorubicin, Camptothecin, Vorinostat, Diindolylmethane etc. are also used for the treatment of various types of cancer. It is worth noting that identified drugs like Resveratrol known for the treatment of high cholesterol, cancer and heart disease and Niclosamide used for treating tapeworm infection are under trials for the treatment of COVID-19 [49,50]. Please note that all the hub proteins involved for KEGG pathway analysis may not have corresponding drugs with FDR corrected p-value less than 5%. Thus, only those hub proteins are reported in Table 4 for which there are corresponding relevant drugs. For example, for NSP2, the hub proteins with corresponding KEGG pathways having FDR corrected p-value less than 5% are NDUFS1, COX4I1, COX5A and COX5B while the hub proteins with relevant drugs having FDR corrected p-values less than 5% are NDUFS1, COX5A and COX5B. Fig. 6 provides a glimpse of the common hub proteins and drugs among multiple SARS-CoV-2 proteins. For example, RPSA is a hub protein common to NSP3, NSP7 and Spike glycoprotein and the corresponding drug that targets RPSA is Disodium Selenite. Please note that though RPSA is also targeted by ORF9b as shown in Table 4, it is not shown in the figure as Disodium Selenite is not a relevant drug for RPSA in ORF9b as the corresponding FDR corrected p-value of Disodium Selenite is not less than 5% in this case. Other drugs like Desipramine, Clindamycin and Vorinostat used as antidepressants,
Fig. 3. A glance into human-SARS-CoV-2 PPI network for (a) NSP1 (b) NSP2 (c) NSP3 (d) NSP4 (e) NSP5 (f) NSP6 (g) NSP7 (h) NSP8 (i) NSP9 (j) NSP10 (k) NSP11 (l) NSP12 (m) NSP13 (n) NSP14 (o) NSP15 (p) Spike glycoprotein (q) ORF3a (r) ORF3a (s) Envelope protein (t) Membrane glycoprotein (u) ORF6 (v) ORF7a (w) ORF7b (x) ORF8 (y) Nucleocapsid (z) ORF9b and (aa) ORF9c and (bb) ORF10. In these figures, nodes marked in blue represent the SARS-CoV-2 proteins, nodes marked in red represent the human hub proteins directly connected to SARS-CoV-2 proteins, green represents the human hub proteins indirectly connected to SARS-CoV-2 proteins and yellow represents other human proteins directly connected to hub proteins.
### Table 3
Details of KEGG Pathways corresponding to Human Hub Proteins for each SARS-CoV-2 Protein.

| Virus   | Human hub proteins | KEGG Pathways related to Comorbidities | FDR corrected p-value | Virus   | Human hub proteins | KEGG Pathways related to Comorbidities | FDR corrected p-value |
|---------|-------------------|----------------------------------------|-----------------------|---------|-------------------|----------------------------------------|-----------------------|
| NSP1    | POLA1, POLA2, PRIM1, PRIM2 | DNA replication | 5.98E-11 | Spike glycoprotein | NSP1    | POLA1, POLA2, PRIM1, PRIM2 | Ribosome | 7.36E-30 |
|         |                    | Pyrimidine metabolism | 1.51E-09 |                 |         | HSPA1, HSPA1L | Protein processing in endoplasmic reticulum | 1.96E-17 |
|         |                    | Purine metabolism | 8.63E-09 |                 |         | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPL0 | RNA transport | 1.03E-09 |
|         |                    | Metabolic pathways | 1.68E-05 |                 |         | HYO1U, P4HB, POIA6, POIA4, EDREM3, ERO1L, TXND5 | Epstein-Barr virus infection | 1.06E-09 |
| NSP2    | NDUF5S1, COX41, COX5A, COX5B | Alzheimer’s disease | 4.51E-06 | ORF3a | NSP1    | POLA1, POLA2, PRIM1, PRIM2 | Parkinon’s disease | 1.50E-04 |
|         |                    | Huntingtons disease | 4.51E-06 |                 |         | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPL0 | Protein processing in endoplasmic reticulum | 4.96E-12 |
|         |                    | Non-alcoholic fatty liver disease (NAFLD) | 4.51E-06 |                 |         | HYO1U, P4HB, POIA6, POIA4, EDREM3, ERO1L, TXND5 | Ribosome | 7.36E-30 |
|         |                    | Oxidative phosphorylation | 4.51E-06 |                 |         | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPL0 | RNA transport | 1.03E-09 |
|         |                    | Parkinson’s disease | 4.51E-06 |                 |         | HYO1U, P4HB, POIA6, POIA4, EDREM3, ERO1L, TXND5 | Legionellosis | 1.06E-09 |
| NSP3    | RPL8, RPSA, RPL12, EEFA1, RPL6, RPL15, RPS11, RPS16, RPL11, RPS15A | Ribosome | 1.72E-26 | ORF3b | NSP1    | POLA1, POLA2, PRIM1, PRIM2 | Prostate cancer | 1.24E-02 |
|         |                    | RNA transport | 5.20E-03 |                 |         | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPL0 | Measles | 9.10E-03 |
|         |                    | Nucleotide excision repair | 1.80E-04 | Envelope protein | NSP1    | POLA1, POLA2, PRIM1, PRIM2 | Influenza A | 9.10E-03 |
|         |                    |               | 1.80E-04 | GAPDH, EEF2, HSP90AA1 |         | HSPA1, HSPA1L | Epstein-Barr virus infection | 9.80E-03 |
|         |                    |               | 1.80E-04 |                 |         | HSPA1, HSPA1L | MAPK signaling pathway | 1.80E-02 |
|         |                    |               | 1.80E-04 |                 |         | HSPA1, HSPA1L | Ampk signaling pathway | 2.50E-04 |
|         |                    |               | 1.80E-04 |                 |         | HSPA1, HSPA1L | PKR-Akt signaling pathway | 4.80E-04 |
|         |                    |               | 1.80E-04 |                 |         | HSPA1, HSPA1L | Prostate cancer | 1.30E-03 |
|         |                    |               | 1.80E-04 |                 |         | HSPA1, HSPA1L | Pathways in cancer | 1.26E-02 |
|         |                    |               | 1.80E-04 |                 |         | HSPA1, HSPA1L | RNA transport | 1.10E-02 |
|         |                    |               | 1.80E-04 |                 |         | HSPA1, HSPA1L | RNA degradation | 3.03E-02 |
| NSP5    | RN1, SEC61A1, CANX, HSP90B1, PSMD6, PSMD14 | Protein processing in endoplasmic reticulum | 2.37E-07 | Membrane glycoprotein | NSP5    | RN1, SEC61A1, CANX, HSP90B1, PSMD6, PSMD14 | mRNA surveillance pathway | 3.03E-02 |
|         |                    | Proteasome | 1.10E-04 |                 |         | HSPA1, HSPA1L | Epstein-Barr virus infection | 8.05E-18 |
|         |                    | Epstein-Barr virus infection | 1.10E-04 |                 |         | HSPA1, HSPA1L | mRNA surveillance pathway | 1.51E-16 |
|         |                    | HTLV1 infection | 3.20E-03 |                 |         | HSPA1, HSPA1L | Influenza A | 3.30E-04 |
|         |                    | Vibri cholaerae infection | 3.39E-02 |                 |         | HSPA1, HSPA1L | Legionellosis | 1.09E-02 |
| NSP6    | ATP5L, ATP6AP1 | Oxidative phosphorylation | 4.60E-04 | ORF6 | NSP6    | ATP5L, ATP6AP1 | Spliceosome | 1.48E-05 |
|         |                    | Metabolic pathways | 2.05E-02 |                 |         | HSPA1, HSPA1L | mRNA surveillance pathway | 3.03E-02 |
| NSP7    | HNRNPA1, EIF4A3, NHP2L1, HSP90B1, PSMD6, PSMD14 | Ribosome | 1.08E-104 | ORF7a | NSP7    | HNRNPA1, EIF4A3, NHP2L1, HSP90B1, PSMD6, PSMD14 | mRNA surveillance pathway | 3.03E-02 |
|         |                    | Spliceosome | 1.00E-02 |                 |         | HSPA1, HSPA1L | Epstein-Barr virus infection | 6.52E-21 |
|         |                    | Epstein-Barr virus infection | 1.18E-07 |                 |         | HSPA1, HSPA1L | mRNA surveillance pathway | 3.03E-02 |
|         |                    | Influenza A | 1.39E-05 |                 |         | HSPA1, HSPA1L | Influenza A | 3.35E-05 |
|         |                    | Legionellosis | 3.60E-04 |                 |         | HSPA1, HSPA1L | Legionellosis | 1.70E-03 |
| NSP8    | NOP58, MPPSOP110, EXOS8C1, XP01, EXOS8C2, EXOS8C5, SRPS4 | RNA degradation | 4.54E-05 | ORF7b | NSP8    | NOP58, MPPSOP110, EXOS8C1, XP01, EXOS8C2, EXOS8C5, SRPS4 | Longevity regulating pathway - multiple species | 1.16E-02 |
|         |                    | Protein export | 4.54E-05 |                 |         | HSPA1, HSPA1L | HIV-1 signaling pathway | 3.92E-02 |
|         |                    | Ribosome biogenesis in eukaryotes | 6.10E-04 |                 |         | HSPA1, HSPA1L | Protein processing in endoplasmic reticulum | 3.18E-15 |
| NSP9    | NUP214, NUP54, NUP62, NUP88, HSPA1A, NUP11 | RNA transport | 2.24E-07 | ORF8 | NSP9    | NUP214, NUP54, NUP62, NUP88, HSPA1A, NUP11 | Phagosome | 3.03E-05 |

(continued on next page)
antibiotic and for treating Cutaneous T-cell lymphoma (CTCL) respectively are also relevant drugs for the human hub proteins targeted by multiple SARS-CoV-2 proteins. Apart from the discussed hub proteins, it is to be noted that as per https://cancer.sanger.ac.uk/cosmic/, other identified hub proteins like XPC in NSP4, RPN1 in NSP5, XPO1 in NSP8, NUP214 in NSP9, PABPC1 and PABPC4 in NSP12, PRKACA in NSP13, SRSF3 and FIP1L1 in ORF7a and CALR in ORF8 are also cancer related human proteins.

5. Conclusion

Comorbidity in COVID-19 patients is one of the primary reasons which have led to so many deaths around the globe. SARS-CoV-2, the virus causing COVID-19, sneaks its way into human body by interacting with the human proteins. In this work, we have identified human and SARS-CoV-2 protein-protein interactions to identify human hub proteins associated with comorbidities. In this regard, we have initially collected 7116 human-SARS-CoV-2 PPI from different works in the literature resulting in identifying 7085 unique PPIs. This can be considered to be a novel and significant contribution of our work. Thereafter, we have considered at most top 10 human hub proteins based on their degrees. Moreover, biological significance of the identified human proteins is demonstrated using KEGG which is essential for identifying the pathways related to diseases or comorbidities. Also, GO Enrichment analysis is performed as well. SARS-CoV-2 proteins like NSP2, NSP5, Envelope and ORF10 interacting with human hub proteins COX4I1, COX5A, COX5B, NDUF5, CANX, HSP90AA1 and TP53 can lead to comorbidities like Alzheimer, Parkinson, Huntington’s, HTLV-1 infection, prostate cancer and viral carcinogenesis. Furthermore, possible repurposable drugs like Disodium Selenite, Desipramine, Clindamycin and Vorinostat targeting the human hub proteins are reported in this paper for future reference for researchers. Also, reported drugs like Resveratrol and Niclosamide are under trials for the treatment of COVID-19. This work provides a consolidated study for human-SARS-CoV-2 protein interactions to understand the association between comorbidity and human hub proteins and we hope it will also be helpful in drug repurposing and discovery as well. To summarise, we have prepared human-SARS-CoV-2 PPI database by curating such PPIs from different works in the literature resulting in 7085 unique PPIs, identified human hub proteins using such PPI networks and identified a list of repurposable drugs for such human hub proteins as well as comorbidity issues related to such hub proteins.

### Table 3 (continued)

| Virus Human hub proteins | KEGG Pathways related to Comorbidities | FDR corrected p-value | Virus Human hub proteins | KEGG Pathways related to Comorbidities | FDR corrected p-value |
|--------------------------|----------------------------------------|-----------------------|--------------------------|----------------------------------------|-----------------------|
| Epstein-Barr virus infection | 0.0336 | | Antigen processing and presentation | 5.80E-03 |
| NSP10 ALDH18A1, ALDH7A1, AP2A2, GALK1 | Arginine and proline metabolism | 2.00E-02 | N-Glycan biosynthesis | 4.66E-02 |
| | Biosynthesis of amino acids | 2.00E-02 | Vibrio cholerae infection | 4.66E-02 |
| | Endocrine and other factor-regulated calcium reabsorption | 2.00E-02 | mRNA surveillance pathway | 6.50E-04 |
| | Synaptic vesicle cycle | 2.00E-02 | RNA transport | 1.70E-03 |
| | Metabolic pathways | 3.70E-02 | RNA degradation | 7.00E-03 |
| NSP11 TUBA1A, TUBA4A, TUBB1, TUBB2A, TUBB4A, TUBB4B | Pathogenic Escherichia coli infection | 4.51E-18 | ORF9b | 3.33E-81 |
| | Gap junction | 9.27E-17 | RPS2O, RPS2O, RPSA | 4.51E-03 |
| | Phagosome | 3.12E-15 | Insulin signaling pathway | 2.72E-02 |
| | Apoptosis | 3.20E-03 | Protein processing in endoplasmic reticulum | 2.23E-02 |
| | Tight junction | 3.90E-03 | Pathogenic Escherichia coli infection | 2.23E-02 |
| NSP12 PABPC1, HSPA8, NCL, PCBP1, RBMIX | Spliceosome | 9.50E-04 | ORF9c | 3.12E-06 |
| | RNA transport | 2.23E-02 | NDUF4F1, NDUF4B, | 3.12E-02 |
| | Protein processing in endoplasmic reticulum | 2.23E-02 | GPAA1, PIGG, PIGS | 1.94E-02 |
| | Pathogenic Escherichia coli infection | 2.23E-02 | | 1.94E-02 |
| NSP13 PRKAR2B, PRKACA | Insulin signaling pathway | 2.72E-02 | ORF10 | 2.07E-20 |
| | | | HSP8A, TP53 | 2.07E-20 |
| | | | Herpes simplex infection | 4.58E-05 |
| | | | Herpes simplex infection | 4.58E-05 |
| | | | Viral carcinogenesis | 1.70E-03 |
| | | | Huntington’s disease | 8.80E-03 |
| | | | Influenza A | 2.21E-02 |
Fig. 4. Significant KEGG pathways corresponding to Hub Proteins for (a) NSP2 (b) NSP5 (c) Envelope protein and (d) ORF10.
Fig. 5. Significant GO Biological Processes corresponding to Hub Proteins for (a) NSP2 (b) NSP5 (c) Envelope protein and (d) ORF10.
Table 4
Details of Drugs corresponding to Human Hub Proteins for each SARS-CoV-2 Protein.

| Virus Protein | Human hub proteins | Drugs | FDR corrected p-value | Drug Bank ID | Treatment | Virus Protein | Human hub proteins | Drugs | FDR corrected p-value | Drug Bank ID | Treatment |
|---------------|-------------------|-------|-----------------------|--------------|-----------|--------------|-------------------|-------|-----------------------|--------------|-----------|
| NSP1          | POLA1, POLA2, PRM1, PRM2 | Dasatinib | 3.96E-05 | DB01254 | Lymphoblastic or chronic myeloid leukemia | ORF3b | HSPA1A, HSPA1L | ≥-Penicillamine | 1.89E-02 | DB00859 | Wilson’s disease |
|               |                   | Resveratrol | 1.38E-03 | DB02709 | High cholesterol, cancer, heart disease | | | | | | |
|               |                   | Demecolcine | 4.67E-03 | DB12318 | Chemotherapy | ORF3b | HSPA1A, HSPA1L | ≥-Penicillamine | 1.89E-02 | DB00859 | Wilson’s disease |
|               |                   | Fluorouracil | 8.35E-03 | DB00544 | Cancer | ORF3b | HSPA1A, HSPA1L | ≥-Penicillamine | 1.89E-02 | DB00859 | Wilson’s disease |
|               |                   | Troglitazone | 3.41E-02 | DB00197 | Type 2 Diabetes | ORF3b | HSPA1A, HSPA1L | ≥-Penicillamine | 1.89E-02 | DB00859 | Wilson’s disease |
| NSP2          | NDUF51, COX5A, COX5B | Vitinoin | 1.31E-02 | DB00755 | Eczema and certain types of promyelocytic leukemia | Envelope Protein | GAPDH, EEF2, HSP90AA1 | Idebenone | 3.38E-03 | DB09081 | Alzheimer’s disease and Leber’s disease |
|               |                   | 3’-Azido-3’-deoxythymidine | 2.00E-02 | DB00495 | HIV | | | | | | |
|               |                   | Artesunate | 8.35E-03 | DB09274 | Malaria | NUP133, POLR2B | Calcitrol | 1.64E-02 | DB00136 | Treat hyperparathyroidism |
|               |                   | Vorinostat | 2.43E-02 | DB02546 | Cutaneous T-cell lymphoma (CTCL) Antibiotic | NUP133, POLR2B | Calcitrol | 1.64E-02 | DB00136 | Treat hyperparathyroidism |
| NSP3          | RPL8, RPSA, RPL12, EEF1A1, RPL6, RPL15, RPS16, RPS15A | Disodium selenite | 2.00E-03 | DB11127 | Prevents Cancer | Membrane glycoprotein | NUP133, POLR2B | Calcitrol | 1.64E-02 | DB00136 | Treat hyperparathyroidism |
|               |                   | Artesunate | 8.35E-03 | DB09274 | Malaria | NUP133, POLR2B | Calcitrol | 1.64E-02 | DB00136 | Treat hyperparathyroidism |
|               |                   | Vorinostat | 2.43E-02 | DB02546 | Cutaneous T-cell lymphoma (CTCL) Antibiotic | NUP133, POLR2B | Calcitrol | 1.64E-02 | DB00136 | Treat hyperparathyroidism |
| NSP5          | SEC61A1, CANX, HSP90B1, PSMD14 | Clindamycin | 9.20E-03 | DB01190 | Tapeworm infection | ORF7a | CPSF1, SRSF3, PRPF8 | Clindamycin | 8.97E-03 | DB01190 | Antibiotic |
|               |                   | Niclosamide | 5.24E-04 | DB06803 | Tapeworm infection | ORF7a | CPSF1, SRSF3, PRPF8 | Clindamycin | 8.97E-03 | DB01190 | Antibiotic |
|               |                   | Vanadium | 5.24E-04 | DB13971 | Diabetes, low blood sugar, high cholesterol, heart disease, tuberculosis, syphilis, preventing cancer | ORF7a | CPSF1, SRSF3, PRPF8 | Clindamycin | 8.97E-03 | DB01190 | Antibiotic |
| NSP7          | NHP2L1, HSP48, RPL4, RPSA, RPS3, RPL8 | Disodium selenite | 8.28E-05 | DB11127 | Prevents Cancer | ORF7b | HSP48, GAPDH | Loxapine | 1.74E-04 | DB00408 | Schizophrenia |
|               |                   | Phenethyl isothiocyanate | 3.37E-02 | DB12695 | Leukemia, Lung Cancer | ORF7b | HSP48, GAPDH | Loxapine | 1.74E-04 | DB00408 | Schizophrenia |
| NSP8          | MPHOSPH10, XP01, EXOSC2, EXOSC5 | 4-Hydroxytamoxifen | 8.13E-03 | DB04468 | Breast cancer | ORF8 | CANX, HSP90B1, CALR, P0A6, Loxapine | 1.74E-04 | DB00408 | Schizophrenia |

(continued on next page)
| Virus Protein | Human hub proteins | Drugs | FDR corrected p-value | Drug Bank ID | Treatment | Virus Protein | Human hub proteins | Drugs | FDR corrected p-value | Drug Bank ID | Treatment |
|---------------|--------------------|-------|----------------------|--------------|-----------|---------------|--------------------|-------|----------------------|--------------|-----------|
| Pergolide     | Daunorubicin       |       | 1.53E-02  3.99E-02   | DB01186      |           | Parkinson’s Disease Acute myeloid leukemia(AML) | Desipramine | Chlorprothixene | 2.54E-04  2.54E-04 | DB01151 DB01239 | Antidepressant Schizophrenia |
| Camptothecin  |                   |       | 4.70E-02   | DB04690      |           | Leukemia      | Clindamycin | Nilutamide | 1.55E-03  3.19E-03 | DB01190 DB00665 | Antibiotic Prostate cancer Antibiotic |
| NSP9          | NUP62, HSPA1A      | Gefitinib | 4.25E-02  4.25E-02 | DB00317      | Lung cancer. Cancer | Nucleocapsid | UPF1       |           |                  |             |           |
| NSP11         | TUBA1A, TUBA4A, TUBB1, TUBB2A, TUBB2B, TUBB4A, TUBB4B | Vinblastine | 6.18E-18   | DB00570      | Cancer Tapeworm infection | ORf9b       | HSP8A, RPSA, EEF1A1, HNRNPA1 | Emetine | 1.24E-02  | DB13393 |           |
| NSP12         | PABPC1, HSPA8, NG2, PCBP1 | Docetaxel | 6.80E-18   | DB01248      | Cancer | Vorinostat | 2.80E-02 | DB02546 | Cutaneous T-cell lymphoma (CTCL) Autism Spectrum Disorder Chemotherapy |
| NSP12         | Fincristine sulfate Sulforaphane | Paclitaxel | 1.34E-16  1.84E-07 | DB01229 | Cancer | Sulforaphane | 3.10E-02 | DB12422 | |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Vincristine sulfate Sulforaphane | 1.34E-16  1.84E-07 | DB00541 | Cancer Prevention of prostate cancer and other types of cancer Prevents Cancer | ORf9c | NDUF88, NDUF89 | Metformin | 2.31E-02  | DB0031 | Type 2 Diabetes |
| ORF3a         | HYOU1, PDIA6, PDIA4, ERO1L, TXNDC5 | Disodium selenite | 3.42E-02  | DB11127 | | | | |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Fulvestrant | 3.42E-02  3.42E-02 | DB00947 | Breast Cancer Brain Tumour | ORf10 | HSP8A, NH23L1, HNRNPA1, RPL4, RPS3, TP53 | Disodium selenite | 9.07E-03  | DB11127 | Prevents Cancer |
| ORF3a         | HYOU1, PDIA6, PDIA4, ERO1L, TXNDC5 | Diindolylmethane | 3.89E-02  | DB02424 | | | | |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Vorinostat | 3.89E-02 | DB02546 | Cutaneous T-cell lymphoma (CTCL) Breast, uterine, and colorectal cancer | Diindolylmethane | 3.89E-02 | DB11875 | |
| ORF3a         | HYOU1, PDIA6, PDIA4, ERO1L, TXNDC5 | Geldanamycin | 2.37E-04  | DB05134 | | | | |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Tanespimycin | 4.19E-04  | DB01151 | | | | |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Emetine | 1.37E-03  7.67E-03 | DB13393 | Several types of cancer, solid tumors or chronic myelogenous leukemia. | Tanespimycin | 4.19E-04  | DB05134 | Several types of cancer, solid tumors or chronic myelogenous leukemia. |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Desipramine | 7.67E-03  7.67E-03 | DB13466 | | | | |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Desipramine | 7.67E-03  | DB01151 | | | | |
| Spike glycoprotein | HSPA8, RPL8, RPS3, RPSA, EEF1A1, RPLP0 | Tanespimycin | 4.19E-04  | DB05134 | | | | |
Ethics approval and consent to participate

The ethical approval or individual consent was not applicable.

Availability of data and materials

The supplementary of this work is available at “http://www.nittrkol.ac.in/indrajit/projects/COVID-PPI/”.

Consent for publication

Not applicable.

Funding

This work has been partially supported by CRG short term research grant on COVID-19 (CVD/2020/000991) from Science and Engineering Research Board (SERB), Department of Science and Technology, Govt. of India.

Author contributions

Nimisha Ghosh: Formal analysis; Methodology, Coding; Visualization; Writing - original draft & editing, Indrajit Saha: Conceptualization; Data curation; Supervision; Funding acquisition; Formal analysis; Investigation; Methodology; Project administration; Resources; Validation; Visualization; Writing - review & editing, Nikhil Sharma: Methodology; Visualization; Writing - review & editing.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgment

We are thankful to the reviewers for improving the quality of the paper by providing constructive comments.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.compbiomed.2021.104889.
